HomeCompareIVIXF vs EPRT

IVIXF vs EPRT: Dividend Comparison 2026

IVIXF yields 5420.05% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IVIXF wins by $136326195118802.17M in total portfolio value
10 years
IVIXF
IVIXF
● Live price
5420.05%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$136326195118802.23M
Annual income
$131,551,666,493,773,860,000.00
Full IVIXF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — IVIXF vs EPRT

📍 IVIXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIVIXFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IVIXF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IVIXF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IVIXF
Annual income on $10K today (after 15% tax)
$460,704.61/yr
After 10yr DRIP, annual income (after tax)
$111,818,916,519,707,770,000.00/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, IVIXF beats the other by $111,818,916,519,707,750,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IVIXF + EPRT for your $10,000?

IVIXF: 50%EPRT: 50%
100% EPRT50/50100% IVIXF
Portfolio after 10yr
$68163097559401.16M
Annual income
$65,775,833,246,886,940,000.00/yr
Blended yield
96.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

IVIXF
No analyst data
Altman Z
-30.2
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IVIXF buys
0
EPRT buys
0
No recent congressional trades found for IVIXF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIVIXFEPRT
Forward yield5420.05%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$136326195118802.23M$63.4K
Annual income after 10y$131,551,666,493,773,860,000.00$12,840.73
Total dividends collected$136003983287005.17M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: IVIXF vs EPRT ($10,000, DRIP)

YearIVIXF PortfolioIVIXF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$552,705$542,005.42$11,205$505.18+$541.5KIVIXF
2$28,588,529$27,997,133.96$12,672$682.46+$28.58MIVIXF
3$1,383,995,048$1,353,405,322.61$14,490$930.48+$1383.98MIVIXF
4$62,714,057,337$61,233,182,635.19$16,786$1,282.69+$62714.04MIVIXF
5$2,660,288,543,813$2,593,184,502,462.66$19,753$1,791.56+$2660288.52MIVIXF
6$105,651,330,702,723$102,804,821,960,842.73$23,677$2,541.64+$105651330.68MIVIXF
7$3,928,761,972,612,137$3,815,715,048,760,222.50$29,008$3,672.99+$3928761972.58MIVIXF
8$136,812,745,737,264,320$132,608,970,426,569,340.00$36,463$5,425.08+$136812745737.23MIVIXF
9$4,462,176,285,073,260,500$4,315,786,647,134,387,700.00$47,238$8,221.57+$4462176285073.21MIVIXF
10$136,326,195,118,802,240,000$131,551,666,493,773,860,000.00$63,385$12,840.73+$136326195118802.17MIVIXF

IVIXF vs EPRT: Complete Analysis 2026

IVIXFStock

Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.

Full IVIXF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this IVIXF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IVIXF vs SCHDIVIXF vs JEPIIVIXF vs OIVIXF vs KOIVIXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.